ECOR
electroCoreDNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-03
Current thesis
ECOR has real commercial traction: 2025 revenue reached $32.0 million, gross margin was 87%, U.S. prescription sales remained strong, and wellness revenue nearly doubled, so a clean 2026 execution year could rerate a stock valued at only about 1.2x trailing sales [#8-K-2026-03-19].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Going-concern and future capital-raise risk
Momentum
79
Value
36
Sentiment
22
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $6.50 · Bull $10.00 · Bear $3.00
Data freshness
Prices
As of 2026-06-03
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-03 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-03
Investment thesis
As of 2026-06-03
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $19.68
Why
Momentum79 · Δ7d -
Value36 · Δ7d -0.0
Sentiment22 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
79
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
36
32% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
22
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 79.4 / Value 36.3 / Sentiment 21.5
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$78.39M
Beta
0.48
Shares Out
8M
P/E (TTM) · Derived
-6.2
P/S (TTM)
1.27
P/FCF (TTM) · Derived
-10.22
Rev YoY
+32.6%
EPS YoY
-30.7%
Gross Margin
+86.0%
Op Margin
-44.5%
Net Debt
-$11.97M
Current Ratio
1.43
As of 2026-06-03 • Updated nightlySource: Internal modelMethodology